Advances in genomic diagnostics have enabled earlier and more precise identification of genetic kidney disease, but the translation of these insights into trial methodology and therapeutic development has lagged. Realizing this potential will require cross-disciplinary coordination, international collaboration, and co-design with patients and communities.
Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.
Read the full paper
Access the original peer-reviewed research via PubMed.
| Category | 🧬 Medicine & Biology |
| Published | Sep 01, 2025 |
| Journal | Seminars in nephrology |
| Authors | Ozimek-Kulik Justyna E, Larkins Nicholas G, Rangan Gopi K, McCarthy Hugh J |
| DOI | 10.1016/j.semnephrol.2025.151650 |
| Source | PubMed |